K. Wilson

发表

Current and future avoidable cost of smoking--estimates for Sweden 2007.

C. Gip, B. Borgman, K. Bolin, 2011, Health policy.

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms

J. McMurray, H. Krum, B. Pitt, 2014, Heart.

A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities.

S. Beard, M. Samuel, K. Wilson, 2011, Journal of evaluation in clinical practice.

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis

K. McCrae, J. Nazir, W. Jurczak, 2021, Advances in Therapy.

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.

E. de Nigris, K. Bolin, H. Aubin, 2009, European journal of public health.

Modeling the Predictive Value of Pain Intensity on Costs and Resources Utilization in Patients With Peripheral Neuropathic Pain

J. Rejas, K. Wilson, C. Pérez, 2015, The Clinical journal of pain.

Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation.

P. Jones, S. Sondhi, K. Wilson, 2003, Respiratory medicine.

Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence.

K. Bolin, A. Mörk, K. Wilson, 2008, Journal of evaluation in clinical practice.

Characterization and treatment of immune thrombocytopenia in Europe: a qualitative observational study

S. Middleton, J. Nazir, W. Jurczak, 2021, Hematology.

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

A. Hatswell, N. Li, K. Wilson, 2019, PharmacoEconomics - Open.

Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden

J. Jovanovic, K. Wilson, N. Henry, 2018, Journal of medical economics.

RO4 COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES

A. Hatswell, K. Wilson, A. Bullement, 2019, Value in Health.

The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting.

M. Toumi, C. Knight, J. Nazir, 2022, Journal of comparative effectiveness research.

A Pharmacoeconomic Evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom

J. Doyle, N. Buller, K. Wilson, 2012, PharmacoEconomics.

Salmeterol/Fluticasone Propionate versus Fluticasone Propionate Plus Montelukast

J. J. Tamminga, S. Sondhi, W. Pieters, 2005, Treatments in respiratory medicine.

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison

M. Duh, R. Wong, K. Wilson, 2023, Advances in Therapy.

The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective

J. E. Matos, J. Panse, H. Costantino, 2022, Hematology.

The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life

J. E. Matos, J. Panse, H. Costantino, 2022, European journal of haematology.

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

H. Sintonen, M. Linna, V. Jormanainen, 2010, Current medical research and opinion.

A Model to Assess the Cost Effectiveness of Statins in Achieving the UK National Service Framework Target Cholesterol Levels

K. Wilson, L. Lacey, J. Marriott, 2012, PharmacoEconomics.

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study

J. McMurray, H. Krum, B. Pitt, 2014 .

The Economic Burden of Stroke in the United Kingdom

L. Kalra, F. Harraf, K. Wilson, 2012, PharmacoEconomics.

Evaluation of varenicline as an aid to smoking cessation in UK general practice – a THIN database study

Michael Metcalfe, A. Maguire, B. Blak, 2010, Current medical research and opinion.

An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy

L. Annemans, R. Hettle, M. Inês, 2012, European journal of preventive cardiology.

Cost-Effectiveness of Varenicline Compared to Placebo as an Aid to Smoking Cessation in Patients with Cardiovascular Disease

R. Hettle, W. Oaks, K. Wilson, 2012 .

Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France

M. Toumi, J. Nazir, P. Wojciechowski, 2023, Journal of comparative effectiveness research.

Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study)

A. Newland, J. Nazir, K. Wilson, 2021, Hematology.

Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data

C. Patriquin, P. Wojciechowski, K. Wilson, 2023, European journal of haematology.

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

A. Hatswell, K. Wilson, A. Bullement, 2020 .

A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities.

S. Beard, M. Samuel, K. Wilson, 2011, Journal of evaluation in clinical practice.

A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease

D. Murphy, J. Riesco, K. Wilson, 2011, Expert opinion on pharmacotherapy.

An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy

L. Annemans, R. Hettle, M. Inês, 2012, European journal of preventive cardiology.

Current and future avoidable cost of smoking--estimates for Sweden 2007.

C. Gip, B. Borgman, K. Bolin, 2011, Health policy.

The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA

D. Dingli, K. Wilson, A. Drzewiecka, 2023, Journal of comparative effectiveness research.